Why the study?
Does the CYP2C19*2 genotype affect the antiplatelet effect and clinical efficacy of clopidogrel therapy?
Does the CYP2C19*2 genotype affect the antiplatelet effect and clinical efficacy of clopidogrel therapy?
The CYP2C19*2 genotype is associated with reduced antiplatelet efficacy of clopidogrel and worse cardiovascular outcomes.
Answers are grounded in this paper and cite their sources.
Warrants caution with clopidogrel in CYP2C19*2 carriers; leaves open whether genotype-guided therapy improves outcomes.
CYP2C19*2 genotype was associated with diminished platelet response to clopidogrel treatment and poorer cardiovascular outcomes.
No takes yet. Share an insight, caveat, or question.
Alan R. Shuldiner (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: